Efanesoctocog alfa
Sponsors
Sanofi, Swedish Orphan Biovitrum
Conditions
Classic HemophiliaFactor VIII DeficiencyHaemophiliaHaemophilia A (Moderate or Severe)HemophiliaHemophilia AHemophilia A, SevereHemophilia, Classic
Phase 1
Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A
CompletedNCT05042440
Start: 2021-08-11End: 2021-11-24Updated: 2025-09-18
Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
CompletedNCT06579144
Start: 2025-02-24End: 2026-05-21Updated: 2026-06-25
Phase 3
A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
CompletedNCT05817812
Start: 2023-07-31End: 2026-06-02Updated: 2026-07-02
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
RecruitingNCT06716814
Start: 2025-03-06End: 2027-03-01Target: 104Updated: 2026-06-26
Phase 4
A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis
Active, not recruitingNCT06752850
Start: 2024-12-19End: 2026-12-28Updated: 2026-04-30
Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
RecruitingNCT06940830
Start: 2025-05-21End: 2028-12-01Target: 250Updated: 2026-06-30
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
RecruitingNCT06941870
Start: 2025-09-23End: 2027-10-25Target: 35Updated: 2025-11-18
Unknown Phase
Goal Attainment and Physical Activity in People With Hemophilia A
TerminatedNCT06530030
Start: 2024-11-26End: 2025-09-18Updated: 2026-01-20
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan
RecruitingNCT06684314
Start: 2024-11-11End: 2031-08-28Target: 100Updated: 2025-10-02